Anixa Biosciences to present ovarian cancer CAR-T data at New York Academy of Sciences cancer immunotherapy symposium

Anixa Biosciences, Inc. - Common Stock

Anixa Biosciences, Inc. - Common Stock

ANIX

0.00
  • Anixa Biosciences will present two clinical-stage immunotherapy programs at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy symposium on June 22-23, 2026.
  • Ovarian cancer CAR-T program lira-cel presentation will highlight positive survival observations from an ongoing Phase 1 trial.
  • Breast cancer alpha-lactalbumin vaccine presentation will cover final Phase 1 results; primary endpoints met; immune responses in 74% of participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606110905PR_NEWS_USPR_____LA81300) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.